Evidence map›Paper›PMID 25935364›Full record

ArticleArchives of biochemistry and biophysics2015

SR-135, a peroxynitrite decomposing catalyst, enhances β-cell function and survival in B6D2F1 mice fed a high fat diet.

Michael Johns, Robert Fyalka, Jennifer A Shea, William L Neumann, Smita Rausaria, Eliwaza Naomi Msengi, Maryam Imani-Nejad, Harry Zollars, Timothy McPherson, Joseph Schober and 2 more

Open access · greenAbstract read
In one paragraph

Article in Archives of biochemistry and biophysics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Consequences of Disturbing Manganese Homeostasis.International journal of molecular sciences · 2023
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Michael JohnsDepartment of Biological Sciences, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Robert FyalkaDepartment of Biological Sciences, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Jennifer A SheaDepartment of Biological Sciences, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
William L NeumannSchool of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Smita RausariaSchool of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Eliwaza Naomi MsengiSchool of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Maryam Imani-NejadSchool of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Harry ZollarsSchool of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Timothy McPhersonSchool of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Joseph SchoberSchool of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Joshua WootenDepartment of Kinesiology and Health Education, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States.
Guim KwonSchool of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026, United States. Electronic address: gkwon@siue.edu.
Southern Illinois University Edwardsville · US

Funding

Targeting the relief of chronic pain with orally active peroxynitrite decompositiRC1AR058231 · NIAMS · SOUTHERN ILLINOIS UNIV AT EDWARDSVILLE · PI NEUMANN, WILLIAM, SALVEMINI, DANIELA · 2009 to 2010
$974k
Human B-cell metabolic signaling under chronic nutrient overloadR15DK094142 · NIDDK · SOUTHERN ILLINOIS UNIV AT EDWARDSVILLE · PI KWON, GUIM · 2012 to 2012
$429k
NIAMS NIH HHS RC1 AR058231NIAMS NIH HHS RC1AR058231NIDDK NIH HHS 1R15DK094142-01A1NIDDK NIH HHS R15 DK094142
6 · The paper itself

Abstract

Peroxynitrite has been implicated in β-cell dysfunction and insulin resistance in obesity. Chemical catalysts that destroy peroxynitrite, therefore, may have therapeutic value for treating type 2 diabetes. To this end, we have recently demonstrated that Mn(III) bis(hydroxyphenyl)-dipyrromethene complexes, SR-135 and its analogs, can effectively catalyze the decomposition of peroxynitrite in vitro and in vivo through a 2-electron mechanism (Rausaria et al., 2011). To study the effects of SR-135 on glucose homeostasis in obesity, B6D2F1 mice were fed with a high fat-diet (HFD) for 12 weeks and treated with vehicle, SR-135 (5mg/kg), or a control drug SRB for 2 weeks. SR-135 significantly reduced fasting blood glucose and insulin levels, and enhanced glucose tolerance as compared to HFD control, vehicle or SRB. SR-135 also enhanced glucose-stimulated insulin secretion based on ex vivo studies. Moreover, SR-135 increased insulin content, restored islet architecture, decreased islet size, and reduced tyrosine nitration and apoptosis. These results suggest that a peroxynitrite decomposing catalyst enhances β-cell function and survival under nutrient overload.

Indexed as

AnimalsApoptosisBlood GlucoseCell SurvivalDiabetes Mellitus, Type 2Diet, High-FatGlucose Tolerance TestHypoglycemic AgentsInsulinInsulin-Secreting CellsMaleManganeseMiceMice, Inbred C57BLObesityPeroxynitrous Acidbis(hydroxyphenyl)dipyrrometheneBlood GlucoseHypoglycemic AgentsInsulinManganesePeroxynitrous AcidPorphobilinogenApoptosisDiabetesInsulinNitrotyrosinePancreatic β-cellPeroxynitrite

Identifiers

PMID25935364
PMCPMC4533897
OpenAlexW2066895810

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.